LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or the "Company"), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that Eef Schimmelpennink, President and Chief Executive Officer, will present and company management will participate in one-on-one meetings at the Jefferies Global Healthcare Conference being held from June 5th- 6th, 2024 in New York City.
聖地亞哥，2024年5月30日（GLOBE NEWSWIRE）——LENZ Therapeutics, Inc.（納斯達克股票代碼：LENZ 或 “LENZ” 或 “公司”）是一家處於臨床後期階段的生物製藥公司，專注於開發首款已被證明可以改善老花眼患者近視力的阿塞利啶滴眼液，該公司今天宣佈，總裁兼首席執行官Eef Schimmelpennink，將在6月5日舉行的傑富瑞全球醫療保健會議上出席，公司管理層將參加一對一的會議第四-6第四，2024 年在紐約市舉行。
Details of the event are as follows:
Date: Thursday, June 6th, 2024
Time: 2:00 p.m. ET
活動詳情如下：
日期：6月6日星期四第四，2024
時間：美國東部時間下午 2:00
The live audio webcast of the presentation can be accessed on the LENZ Therapeutics website at in the Investors & Media section. A replay of the webcast will be available on the Company's website for 30 days following the event.
該演講的網絡直播可在LENZ Therapeutics網站上的 “投資者與媒體” 欄目上觀看。網絡直播的重播將在活動結束後的30天內在公司網站上播放。
About LENZ Therapeutics
LENZ Therapeutics is a late clinical-stage biopharmaceutical company focused on the development and commercialization of the first aceclidine-based eye drop to improve vision in patients with presbyopia. LENZ's product candidate, LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for "all eyes, all day." LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
關於 LENZ 療法
LENZ Therapeutics是一家處於臨床後期階段的生物製藥公司，專注於開發和商業化首款以阿塞利啶爲基礎的眼藥水，以改善老花眼患者的視力。LENZ 的候選產品，LNZ100 是一種不含防腐劑、一次性使用、每天一次的眼藥水，含有醋利定。在支持註冊的 3 期 CLARITY 研究中，LNZ100 被評估爲一種治療老花眼的潛在療法，這種疾病估計影響了全球18億人和美國1.28億人。LENZ 致力於將理想的藥物老花眼解決方案商業化，以增強 “全眼一整天” 的視力。LENZ 總部位於加利福尼亞州聖地亞哥。欲了解更多信息，請訪問：Lenz-TX.com。
Contacts:
聯繫人：
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
丹·切瓦拉德
LENZ 療法
IR@LENZ-Tx.com
譯文內容由第三人軟體翻譯。